Magnetic hydroxyapatite nanomaterial–cyclodextrin tethered polymer hybrids as anticancer drug carriers

Osteosarcoma, the most common bone cancer, leads to a poor survival rate of patients. Drug targeting employing hydroxyapatite (HAp)-based nanocarriers represents a fascinating choice for non-invasive treatment of osteosarcoma.

Download Full-text

Urine Biomarkers for the Early Detection of Ovarian Cancer – Are We There Yet?

Biomarkers in Cancer ◽

10.1177/1179299x19830977 ◽

2019 ◽

Vol 11 ◽

pp. 1179299X1983097 ◽

Cited By ~ 11

Author(s):

Kelly Grayson ◽

Ebony Gregory ◽

Ghazala Khan ◽

Barbara-Ann Guinn

Keyword(s):

Ovarian Cancer ◽

Survival Rate ◽

Screening Strategy ◽

Diagnostic Methods ◽

Cancer Antigen 125 ◽

Poor Survival ◽

Non Invasive ◽

The United Kingdom ◽

Urine Biomarkers ◽

Late Stage Diagnosis

Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Current diagnostic methods are invasive and consist of a pelvic examination, transvaginal ultrasonography, and blood tests to detect cancer antigen 125 (CA125). Unfortunately, surgery is often still required to make a positive diagnosis. To address the need for accurate, specific, and non-invasive diagnostic methods, there has been an increased interest in biomarkers identified through non-invasive tests as tools for the earlier diagnosis of ovarian cancer. Although most studies have focused on the identification of biomarkers in blood, the ease of availability of urine and the high patient compliance rates suggest that it could provide a promising resource for the screening of patients for ovarian cancer.

Download Full-text

Magnetic stimulation scores modest success as antidepressant trial of non-invasive treatment used new, convincing sham control

PsycEXTRA Dataset ◽

10.1037/e650002010-001 ◽

2010 ◽

Keyword(s):

Magnetic Stimulation ◽

Sham Control ◽

Invasive Treatment ◽

Non Invasive

Download Full-text

Advances in Nanoparticles as Anticancer Drug Delivery Vector: Need of this Century

Current Pharmaceutical Design ◽

10.2174/1381612826666200203124330 ◽

2020 ◽

Vol 26 (15) ◽

pp. 1637-1649 ◽

Cited By ~ 3

Author(s):

Imran Ali ◽

Sofi D. Mukhtar ◽

Heyam S. Ali ◽

Marcus T. Scotti ◽

Luciana Scotti

Keyword(s):

Drug Delivery ◽

Anticancer Drug ◽

Medical Science ◽

Drug Carriers ◽

Anticancer Drug Delivery ◽

Ph Values ◽

Delivery Vector ◽

Future Challenges ◽

Smart Drug ◽

Smart Drug Delivery

Background: Nanotechnology has contributed a great deal to the field of medical science. Smart drugdelivery vectors, combined with stimuli-based characteristics, are becoming increasingly important. The use of external and internal stimulating factors can have enormous benefits and increase the targeting efficiency of nanotechnology platforms. The pH values of tumor vascular tissues are acidic in nature, allowing the improved targeting of anticancer drug payloads using drug-delivery vectors. Nanopolymers are smart drug-delivery vectors that have recently been developed and recommended for use by scientists because of their potential targeting capabilities, non-toxicity and biocompatibility, and make them ideal nanocarriers for personalized drug delivery. Method: The present review article provides an overview of current advances in the use of nanoparticles (NPs) as anticancer drug-delivery vectors. Results: This article reviews the molecular basis for the use of NPs in medicine, including personalized medicine, personalized therapy, emerging vistas in anticancer therapy, nanopolymer targeting, passive and active targeting transports, pH-responsive drug carriers, biological barriers, computer-aided drug design, future challenges and perspectives, biodegradability and safety. Conclusions: This article will benefit academia, researchers, clinicians, and government authorities by providing a basis for further research advancements.

Download Full-text

Carbon Dioxide Laser Vulvovaginal Rejuvenation: A Systematic Review

Cosmetics ◽

10.3390/cosmetics8030056 ◽

2021 ◽

Vol 8 (3) ◽

pp. 56

Author(s):

Tassahil Messas ◽

Achraf Messas ◽

George Kroumpouzos

Keyword(s):

Carbon Dioxide ◽

Systematic Review ◽

Laser Therapy ◽

Carbon Dioxide Laser ◽

Invasive Treatment ◽

Erbium:Yag Laser ◽

Non Invasive ◽

Level I ◽

Carbon Dioxide Co2

Genitourinary syndrome of menopause (GSM) causes significant symptomatic aggravation that affects the quality of life (QoL). Vulvovaginal atrophy (VVA), the hallmark of GSM, is managed with topical non-hormonal therapy, including moisturizers and lubricants, and topical estrogen application. Patients not responding/being unsatisfied with previous local estrogen therapies are candidates for a noninvasive modality. Carbon dioxide (CO2) laser therapy, especially the fractionated type (FrCO2), has drawn considerable attention over the past two decades as a non-invasive treatment for GSM. This systematic review describes the accumulated evidence from 40 FrCO2 laser studies (3466 participants) in GSM/VVA. MEDLINE, Scopus and Cochrane databases were searched through April 2021. We analyze the effects of FrCO2 laser therapy on symptoms, sexual function, and QoL of patients with GSM/VVA. As shown in this review, FrCO2 laser therapy for GSM shows good efficacy and safety. This modality has the potential to advance female sexual wellness. Patient satisfaction was high in the studies included in this systematic review. However, there is a lack of level I evidence, and more randomized sham-controlled trials are required. Furthermore, several clinical questions, such as the number of sessions required that determine cost-effectiveness, should be addressed. Also, whether FrCO2 laser therapy may exert a synergistic effect with systemic and/or local hormonal/non-hormonal treatments, energy-based devices, and other modalities to treat GMS requires further investigation. Lastly, studies are required to compare FrCO2 laser therapy with other energy-based devices such as erbium:YAG laser and radiofrequency.

Download Full-text

Non-invasive MRS in new anticancer drug development

NMR in Biomedicine ◽

10.1002/nbm.1940050513 ◽

1992 ◽

Vol 5 (5) ◽

pp. 270-272 ◽

Cited By ~ 12

Author(s):

Paul Workman ◽

Ross J. Maxwell ◽

John R. Griffiths

Keyword(s):

Drug Development ◽

Anticancer Drug ◽

Non Invasive ◽

Anticancer Drug Development

Download Full-text

Preparation ofN-Isopropylacrylamide/Itaconic Acid Magnetic Nanohydrogels by Modified Starch as a Crosslinker for Anticancer Drug Carriers

International Journal of Polymeric Materials ◽

10.1080/00914037.2014.996703 ◽

2015 ◽

Vol 64 (10) ◽

pp. 541-549 ◽

Cited By ~ 32

Author(s):

Marziyeh Fathi ◽

Ali Akbar Entezami ◽

Sanam Arami ◽

Mohammad-Reza Rashidi

Keyword(s):

Anticancer Drug ◽

Itaconic Acid ◽

Drug Carriers ◽

Modified Starch

Download Full-text

Contemporary Treatment for Central Serous Chorioretinopathy

Journal of Clinical and Medical Research ◽

10.37191/mapsci-2582-4333-3(5)-089 ◽

2021 ◽

Author(s):

Mitova D

Keyword(s):

Subretinal Fluid ◽

Functional Results ◽

Clinical Results ◽

Long Term Results ◽

Nanosecond Laser ◽

Success Rates ◽

Invasive Treatment ◽

Non Invasive ◽

Short And Long Term

Aim: To study the short-and long-term results of 2RT nanosecond laser treatment for CSC. To compare clinical results with those with AntiVEGF. Methods: Nanosecond laser (2RT, Ellex) was used. Patients were followed by BCVA, FAF, OCT, Angio-OCT. Results: 90% of the patient treated with 2RT had improvement of visual acuity and contrast sensitivity. 19 % [1] patients showed no improvement. 81% of the 2RT treated patients had total resorbtion of subretinal fluid against 60% treated with AntiVEGF. Functional results correlated with the atrophy of RPE in the macula. 46% (19 patients) had resolution on the first month, 23% [2]-on the third and 12% [3]-on the sixth month. The time of resolution shows no relation to the baseline pigment epithelial atrophy. Four patients presented with a recurrency of the disease in the follow-up period. 19% [1] were non responders. 60% of AntiVEGF treated eyes were responders and 40% were non responders. Those who responded to treatment needed between 3 and 10 injections. Conclusion: 2 RT is a non-invasive treatment modality with no adverse effects and high success rates.

Download Full-text

Bichromophoric anticancer drug: Targeting lysosome with rhodamine modified cyclometalated Iridium(III) complexes

Dyes and Pigments ◽

10.1016/j.dyepig.2018.10.019 ◽

2019 ◽

Vol 162 ◽

pp. 385-393 ◽

Cited By ~ 21

Author(s):

Wenli Ma ◽

Xingxing Ge ◽

Lihua Guo ◽

Shumiao Zhang ◽

JuanJuan Li ◽

...

Keyword(s):

Anticancer Drug ◽

Drug Targeting

Download Full-text

Management of bladder stones: the move towards non-invasive treatment

Medical Journal of Indonesia ◽

10.13181/mji.v26i2.1602 ◽

2017 ◽

Vol 26 (2) ◽

pp. 128-33 ◽

Cited By ~ 1

Author(s):

Isaac A. Deswanto ◽

Ari Basukarno ◽

Ponco Birowo ◽

Nur Rasyid

Keyword(s):

Hospital Stay ◽

Bladder Stone ◽

Outpatient Basis ◽

Invasive Treatment ◽

Invasive Approach ◽

Bladder Calculi ◽

Bladder Stones ◽

Non Invasive ◽

Extracorporeal Shock Wave ◽

Intracorporeal Lithotripsy

Background: Bladder stone accounts for 5% of all cases of urolithiasis. Bladder stones management has evolved over the last decades from open bladder surgery (sectio alta) to intracorporeal cystholithotripsy as well as extracorporeal shock wave lithotripsy (ESWL). ESWL presents to be a promising modality in the management of bladder calculi due to its simplicity and well tolerability. This study is thus conducted to present data on the safety and effectiveness of ESWL in the management of bladder stone patients.Methods: This is a retrospective study evaluating the medical records of 92 bladder calculi patients admitted to Cipto Mangunkusumo General Hospital (RSCM) from January 2011 to April 2015. Patient’s age, gender, type of stone and procedure being done, status of stone disintegration, length of hospital stay, and any complications that may occur are noted down and statistically analyzed using SPSS v. 20.Results: Majority of the patients underwent ESWL (49 out of 92, 53.3%). The stone free rates for ESWL, intracorporeal lithotripsy, and sectio alta are 93.9%, 97.0% and 100% respectively. One patient had to repeat ESWL. The ESWL group had the smallest stone size average compared to the intracorporeal lithotripsy and section alta group (2.5 cm±2.0 cm vs 4.8 cm±3.7 cm vs 7.4 cm±5.4 cm respectively). The ESWL sessions were conducted in the outpatient clinic, and thus no hospital stay was required.Conclusion: ESWL can be suggested as an effective non-invasive approach in the disintegration of bladder stone of ≤25 mm with a promisingly high stone-free rate (93.9%) Furthermore, ESWL can be performed on an outpatient basis with minimal complications.

Download Full-text